• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Upadacitinib for the Treatment of Atopic Dermatitis

Video

Emma Guttman-Yassky, MD, sits down with Dermatology Times® to discuss recently published results of a phase 3 study evaluating upadacitinib (Rinvoq, AbbVie) as a potential treatment of atopic dermatitis.

Related Videos
Video 5 - featuring 2 panelists in, "Quality of Life + Closing Thoughts
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 2 - featuring 2 panelists in, "Empowering Patients: Understanding New Treatments and Long-Term Considerations with Fresh Approaches and FDA Endorsements "
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Related Content
FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

FDA Approves Biosimilar Ustekinumab-ttwe for All Indications of Reference Medicine

Article
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Podcast
Turn Therapeutics' Atopic Dermatitis Candidate Achieves 57% Reduction in Disease Severity in 7 Days

Turn Therapeutics' Atopic Dermatitis Candidate Achieves 57% Reduction in Disease Severity in 7 Days

Article
PODCAST: From Infection to Innovation - The Turn Therapeutics Story

PODCAST: From Infection to Innovation - The Turn Therapeutics Story

Podcast
Health Canada Authorizes Lebrikizumab for Moderate to Severe Atopic Dermatitis in Patients 12 Years and Older

Health Canada Authorizes Lebrikizumab for Moderate to Severe Atopic Dermatitis in Patients 12 Years and Older

Article
Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

Article
© 2024 MJH Life Sciences

All rights reserved.